Ann maintains relationships with many people - family, friends. Other names that Ann uses includes Ann F Faulkner, Ann Faulknersaruk, Schoemaker Anne Faulkner, Anne Faulkner Schoemaker and Anne F Schoemaker. Right now, Ann Faulkner lives in Philadelphia, PA. But these and other hurdles shouldn't obscure the growing opportunity. Ann Faulkner is 73 years old and was born on. Nonetheless, the stem cell industry has remained a start-up's trade, and it's easy to see why: large-company experiences in the area have not, for the most part, been happy ones, as companies face the issues of installing unpharma-like infrastructures to deliver personalized therapy, as well as ethical concerns, which must be given appropriate consideration. The transplant replacement business-regenerative medicine-has caught the public's attention. Meanwhile, researchers have transformed fully committed adult stem cells into cells of different lineages, raising the possibility that alternatives to ESCs for tissue replacement or repair exist. The time is right to get into the blossoming field of stem cells, believes the high-profile founder of Neuronyx Inc., Hubert Schoemaker, PhD.
But recent developments have stirred the competitive pot: a number of companies have created methods for growing enough adult stem cells to provide them to significant numbers of patients. Geron, the only player in this group to have benefited from the last nine months of biotech stock mania, holds a key competitive advantage: its ability to use embryonic stem cells (ESCs) to create, theoretically, nearly infinite quantities of any cell in the body. For the most part, companies have had to propose autologous transplantation strategies or, at best, transplants from one donor for just a few patients-an economically difficult-to-justify business. Beyond the lack of clinical conformation, stem cell transplantation therapy has been held back by the inability to culture large quantities of cells-as with whole organ transplants, there simply isn't enough tissue to go around. Stem cell trials are finally in progress, allowing investors and corporate partners to finally see just how effective this multi-billion-dollar opportunity to replace many highly problematic organ transplants, and dramatically expand the procedures into new areas, can be. Physicians, patients, and companies can now see the stem cell transplant business taking shape.
0 kommentar(er)
